Analytical Validation and Clinical Sensitivity of the Belay Summit™ 2.0 Cerebrospinal Fluid Liquid Biopsy Test—An Expanded Comprehensive Genomic Profiling Platform for Central Nervous System Malignancies
These findings support the use of the Belay Summit™ 2.0 assay for accurate and reproducible genomic profiling of CNS tumors using tumor-derived nucleic acids from CSF in patients for whom tissue-based testing is considered infeasible, unsafe, or not deemed by the prescribing physician to be clinically appropriate.
Authors
- Samer Al-Saffar
- C. Bettegowda
- Christopher Douville (ORCID: https://orcid.org/0000-0002-2510-4151)
- J ADAMS
- Kala F. Schilter (ORCID: https://orcid.org/0000-0001-8061-0842)
- Vindhya Udhane
- Anthony Acevedo
- Alexandra Larson (ORCID: https://orcid.org/0000-0002-2163-2125)
- Dean Ellis
- Honey V. Reddi (ORCID: https://orcid.org/0000-0003-1280-9993)
- Qian Nie (ORCID: https://orcid.org/0000-0003-2952-9998)
- Kaye Mitchell
- Samantha A Vo
- Brett A Domagala
- Baymuhammet Muhammedov
- Sakshi Khurana
- Tarin Peltier
- Kyle M. Hernandez
- Viriya Keo
- Daniel Sanchez
Institutions
- Johns Hopkins University (US)
- Johns Hopkins Medicine (US)
- University of Chicago (US)
Publication Details
- Journal
- Cancers
- Published
- 2026-01-14
- DOI
- https://doi.org/10.3390/cancers18020256
- Citations
- 1
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 24.82